Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MYC006
MIFTS: 72

Mycosis Fungoides

Categories: Rare diseases, Cancer diseases, Skin diseases, Blood diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Mycosis Fungoides

About this section

MalaCards integrated aliases for Mycosis Fungoides:

Name: Mycosis Fungoides 57 38 12 76 53 25 37 55 44 15 73
Mycosis Fungoides Lymphoma 12 76
Alibert-Bazin Syndrome 53 25
Granuloma Fungoides 53 25
Mycosis Fungoides of Unspecified Site 12
Mycosis Fungoides, Alibert-Bazin Type 59
Classic Mycosis Fungoides 59
Mf 12

Characteristics:

Orphanet epidemiological data:

59
classic mycosis fungoides
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult;

OMIM:

57
Inheritance:
familial aggregation without simple mendelian pattern


Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Skin diseases Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare skin diseases
Rare haematological diseases


Sources

Summaries for Mycosis Fungoides

About this section
OMIM : 57 Mycosis fungoides is a malignant T-cell lymphoma of the skin, first reported (and named) by Alibert (1835). Sezary syndrome is a leukemic variant of mycosis fungoides defined by erythroderma with greater than 80% of the skin showing redness, adenopathy and greater than 1,000 circulating Sezary cells/microliter with a CD4+CD26- or CD4+CD7- phenotype. Sezary cells have a type 2 helper T cell cytokine profile. Sezary syndrome has a median overall survival time of only 2.4 years in patients with Sezary cells at a density of greater than 10,000 cells/microliter or 5.4 years in patients with 1,000-10,000 Sezary cells/microliter. Mycosis fungoides and Sezary syndrome are the most common cutaneous T-cell lymphomas. Sezary syndrome can arise de novo or can appear following years of chronic mycosis fungoides. Both are thought to arise from clonal expansion of CD4+ helper T cells responding to chronic antigen stimulation (summary by Wang et al., 2015). (254400)

MalaCards based summary : Mycosis Fungoides, also known as mycosis fungoides lymphoma, is related to cutaneous t cell lymphoma and follicular mucinosis. An important gene associated with Mycosis Fungoides is TNFRSF1B (TNF Receptor Superfamily Member 1B), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Abraxane and Methoxsalen have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and bone, and related phenotypes are splenomegaly and hepatomegaly

NIH Rare Diseases : 53 Mycosis fungoides is a disease in which T-celllymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin. This condition is one of the most common types of T-cell lymphoma. Mycosis fungoides is characterized by a scaly, red rash that develops on the skin, particularly on areas that are not usually exposed to the sun. The rash may last for months or years without causing any symptoms. Over time, a thin, reddened, eczema-like rash may develop, followed by thickened, red patches of skin. Finally, tumors form which may develop into ulcers and become infected. Mycosis fungoides is difficult to cure. Treatment is usually palliative, with the intention of relieving symptoms and improving the quality of life.

Genetics Home Reference : 25 Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. Although the skin is involved, the skin cells themselves are not cancerous. Mycosis fungoides usually occurs in adults over age 50, although affected children have been identified.

Wikipedia : 76 Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form... more...

Sources

Related Diseases for Mycosis Fungoides

About this section

Diseases related to Mycosis Fungoides via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
# Related Disease Score Top Affiliating Genes
1 cutaneous t cell lymphoma 32.2 CCL17 CCR4 IFNA1 IL2 IL2RA TIA1
2 follicular mucinosis 32.0 CD7 IFNA2 TNFRSF8
3 pityriasis lichenoides 31.8 CD7 TNFRSF8
4 dermatitis 31.5 CCL17 CCL22 IL5 STAT3
5 adult t-cell leukemia 31.3 CD7 IL2 IL2RA TNFRSF8
6 lymphoma, hodgkin, classic 31.1 CCL17 IL2 TIA1
7 t-cell leukemia 31.0 CCR4 CD7 IL2 IL2RA TNFRSF8
8 wells syndrome 31.0 IL2 IL2RA IL5
9 psoriasis 31.0 CCL17 CCL22 CXCR3 IL2 TNFRSF1B
10 cryoglobulinemia, familial mixed 30.8 IFNA1 IFNA2
11 hypereosinophilic syndrome 30.8 CCL17 IFNA1 IL2RA IL5
12 alopecia areata 30.7 CTLA4 IL2 IL2RA
13 lymphoma, non-hodgkin, familial 30.6 CDKN2B IL2 IL2RA TNFRSF8
14 leukemia, chronic lymphocytic 30.6 CXCR3 IL2 IL2RA STAT3 TNFRSF8
15 dermatitis, atopic 30.5 CCL17 CCL22 CCR4 CXCR3 IL2 IL2RA
16 uveitis 30.5 CTLA4 CXCR3 IFNA2 IL2RA
17 peripheral t-cell lymphoma 30.4 CCR4 CXCR3 IL2 TIA1 TNFRSF8
18 leukemia, acute myeloid 30.3 CD7 CDKN2B IL2 STAT3
19 hairy cell leukemia 30.2 IFNA1 IFNA2 IL2 IL2RA ITGAE
20 sezary's disease 30.1 CCR4 CD28 CD7 CTLA4 DPP4 IFNA1
21 multiple sclerosis 30.0 CTLA4 CXCR3 IFNA1 IL2 IL2RA IL5
22 systemic lupus erythematosus 29.6 CTLA4 CXCR3 IFNA1 IL2 IL2RA TNFRSF1B
23 folliculotropic mycosis fungoides 12.5
24 marfan syndrome 11.9
25 extranodal nasal nk/t cell lymphoma 11.1
26 shprintzen-goldberg craniosynostosis syndrome 11.0
27 monofixation syndrome 11.0
28 pityriasis lichenoides et varioliformis acuta 11.0 CD7 TNFRSF8
29 paragonimiasis 11.0 CCL17 CXCR3 IL5
30 erythema multiforme 11.0 CCL17 CXCR3 IL2
31 atopic keratoconjunctivitis 10.9 CCL22 IL2 IL5
32 necatoriasis 10.9 CCL17 CCL22 IL5
33 apple allergy 10.9 CCL17 CCL22 IL5
34 neonatal marfan syndrome 10.9
35 squamous papillomatosis 10.9 IFNA1 IFNA2
36 intermediate uveitis 10.9 CXCR3 IL2 IL2RA
37 radiculopathy 10.9 CXCR3 IL2RA IL5
38 keratoconjunctivitis 10.9 CCL17 IL2 IL5
39 lymphoma 10.9
40 homocystinuria due to cystathionine beta-synthase deficiency 10.9
41 microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma 10.9
42 leukocyte disease 10.9 IFNA1 IL2 IL5
43 allergic contact dermatitis 10.9 CCL17 CXCR3 IL5
44 eosinophilic pneumonia 10.9 CCL17 CCL22 IL5
45 fixed drug eruption 10.9 CCR4 IL2
46 tropical spastic paraparesis 10.9 CXCR3 IL2 IL2RA
47 pulmonary sarcoidosis 10.8 CXCR3 IL2 IL2RA
48 granulomatous slack skin disease 10.8
49 recurrent respiratory papillomatosis 10.8 IFNA2 IL2
50 pure red-cell aplasia 10.8 IL2 IL2RA STAT3

Graphical network of the top 20 diseases related to Mycosis Fungoides:



Diseases related to Mycosis Fungoides
Sources

Symptoms & Phenotypes for Mycosis Fungoides

About this section

Symptoms via clinical synopsis from OMIM:

57
Skin:
pruritus
erythema
psoriasiform dermatitis
malignant t-cell skin lymphoma
skin scaling
more
Lymphatics:
lymphadenopathy


Clinical features from OMIM:

254400

Human phenotypes related to Mycosis Fungoides:

59 32 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001744
2 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
3 abnormality of the nail 59 32 occasional (7.5%) Occasional (29-5%) HP:0001597
4 hyperkeratosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000962
5 edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0000969
6 pruritus 59 32 hallmark (90%) Very frequent (99-80%) HP:0000989
7 dry skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0000958
8 alopecia 59 32 frequent (33%) Frequent (79-30%) HP:0001596
9 skin ulcer 59 32 occasional (7.5%) Occasional (29-5%) HP:0200042
10 hypopigmented skin patches 59 32 frequent (33%) Frequent (79-30%) HP:0001053
11 irregular hyperpigmentation 59 32 frequent (33%) Frequent (79-30%) HP:0007400
12 neoplasm of the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0008069
13 erythema 59 32 hallmark (90%) Very frequent (99-80%) HP:0010783
14 skin rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0000988
15 eczema 59 32 hallmark (90%) Very frequent (99-80%) HP:0000964
16 lymphoma 59 32 Very frequent (99-80%) HP:0002665
17 lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0002716
18 abnormality of bone marrow cell morphology 59 32 occasional (7.5%) Occasional (29-5%) HP:0005561
19 skin plaque 59 32 hallmark (90%) Very frequent (99-80%) HP:0200035
20 poikiloderma 59 32 frequent (33%) Frequent (79-30%) HP:0001029
21 cutaneous t-cell lymphoma 59 32 frequent (33%) Frequent (79-30%) HP:0012192
22 abnormality of the eyelid 59 Occasional (29-5%)
23 psoriasiform dermatitis 32 HP:0003765
24 abnormality of lymphocytes 59 Very frequent (99-80%)
25 abnormal eyelid morphology 32 occasional (7.5%) HP:0000492
26 abnormal lymphocyte morphology 32 hallmark (90%) HP:0004332

MGI Mouse Phenotypes related to Mycosis Fungoides:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.16 CCL17 CCR4 CD28 CD7 CDKN2B CTLA4
2 immune system MP:0005387 10.09 TNFRSF1B TNFRSF8 CCL17 CCL22 CCR4 CD28
3 endocrine/exocrine gland MP:0005379 10.02 CD28 CD7 CDKN2B CTLA4 DPP4 IL2
4 digestive/alimentary MP:0005381 9.91 CD28 CTLA4 IL2 IL2RA IL5 STAT3
5 neoplasm MP:0002006 9.5 CD28 CDKN2B CXCR3 IL2 IL5 STAT3
6 respiratory system MP:0005388 9.23 CCR4 CTLA4 CXCR3 IL2 IL2RA IL5
Sources

Drugs & Therapeutics for Mycosis Fungoides

About this section

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012

Drugs for Mycosis Fungoides (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 363)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 298-81-7 4114
2
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 153559-49-0 82146
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
4
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Not Applicable 173146-27-5
5
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
6
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
7 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
14 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
17 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2,Not Applicable
20 Interferon-alpha Phase 4,Phase 2,Not Applicable
21 interferons Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Clorazepate Dipotassium Phase 4
23 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
26
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
27
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
28
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
29
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
30
Ofloxacin Approved Phase 3 82419-36-1 4583
31
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
32
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
33
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
34
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 4053 460612
35
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
36
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 23214-92-8 31703
37
Panobinostat Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 404950-80-7 6918837
38
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
39
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
40
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
41
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
42
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
43
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
44
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 93-14-1 3516
45
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
46
Ondansetron Approved Phase 3,Phase 2,Not Applicable 99614-02-5 4595
47
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
48
Captopril Approved Phase 3 62571-86-2 44093
49
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
50
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365

Interventional clinical trials:

(show top 50) (show all 386)
# Name Status NCT ID Phase Drugs
1 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
2 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
3 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
4 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
5 Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Recruiting NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
6 PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
10 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3 Panobinostat
11 Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma Completed NCT00490776 Phase 2, Phase 3 LBH589
12 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
13 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
14 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
15 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
16 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
17 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
18 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
19 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
20 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
21 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
22 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
23 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
24 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
25 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
26 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
27 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
28 Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides Recruiting NCT03454945 Phase 3 Vibramycin
29 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Recruiting NCT02448381 Phase 3 SGX301 (synthetic hypericin);Placebo
30 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Recruiting NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
31 PUVA Maintenance Therapy in Mycosis Fungoides Active, not recruiting NCT01686594 Phase 3 8-methoxypsoralen
32 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) Active, not recruiting NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate;Bexarotene
33 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
34 Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
35 Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides Terminated NCT00056056 Phase 3 bexarotene;methoxypsoralen
36 Lenalidomide Maintenance Post-debulking in Advanced CTCL Terminated NCT01098656 Phase 3 lenalidomide
37 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
38 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
39 Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
40 Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome Unknown status NCT00157274 Phase 2 alemtuzumab
41 Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides Unknown status NCT00002557 Phase 2 CHOP regimen;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate
42 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
43 Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma Unknown status NCT00030589 Phase 2 bexarotene;methoxsalen
44 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
45 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
46 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
47 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
48 Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides Completed NCT00168064 Phase 2 mechlorethamine-MCH (nitrogen mustard)
49 Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome Completed NCT02243579 Phase 2
50 An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides Completed NCT00535470 Phase 2 0.04% Mechlorethamine gel

Search NIH Clinical Center for Mycosis Fungoides

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mycosis Fungoides cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Mycosis Fungoides:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Mycosis Fungoides:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: mycosis fungoides

Sources

Genetic Tests for Mycosis Fungoides

About this section
Sources

Anatomical Context for Mycosis Fungoides

About this section

MalaCards organs/tissues related to Mycosis Fungoides:

41
T Cells, Skin, Bone, Bone Marrow, B Cells, Lung, Liver
Sources

Publications for Mycosis Fungoides

About this section

Articles related to Mycosis Fungoides:

(show top 50) (show all 1170)
# Title Authors Year
1
Increased interleukin-36I^ expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/SAczary syndrome. ( 29314201 )
2018
2
Mycosis fungoides in patients with psoriasis: an ongoing issue. ( 29336316 )
2018
3
Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms. ( 29341283 )
2018
4
Dual-Positive CD4/CD8 Primary Cutaneous Peripheral T-Cell Lymphoma Previously Classified as Mycosis Fungoides a Tumor D'EmblAce. ( 29794483 )
2018
5
How to Discern Folliculotropic Mycosis Fungoides From Follicular Mucinosis Using a Pediatric Case. ( 29318909 )
2018
6
Total Skin Electron Irradiation and Sequential Malignancies in Mycosis Fungoides Patients: Longitudinal Study. ( 29945743 )
2018
7
Immune privilege disruption in folliculotropic mycosis fungoides: investigation of major histocompatibility complex antigen expression. ( 29603194 )
2018
8
Dermoscopic patterns of early-stage mycosis fungoides in a Chinese population. ( 29876963 )
2018
9
CADM1 is a diagnostic marker in early-stage mycosis fungoides: Multicenter study of 58 cases. ( 29928911 )
2018
10
Pediatric CD8+/CD56+ mycosis fungoides with cytotoxic marker expression: a variant with indolent course. ( 29968317 )
2018
11
Intraocular involvement of mycosis fungoides associated with immunophenotypic switch from CD4+ to CD8. ( 29298755 )
2018
12
Type D (CD8+) lymphomatoid papulosis in a patient with classic (CD4+) mycosis fungoides. ( 29378678 )
2018
13
Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis. ( 29733229 )
2018
14
Verrucous mycosis fungoides. ( 29417797 )
2018
15
Current systemic therapeutic options for advanced mycosis fungoides and SAczary syndrome. ( 29308723 )
2018
16
Methotrexate in the treatment of mycosis fungoides - a multicenter observational study in 79 patients. ( 29917213 )
2018
17
The Effectiveness of a Twice-weekly Narrowband Ultraviolet B Phototherapy Schedule in Early-stage Mycosis Fungoides in a Cohort of 18 Argentinian Patients. ( 29908635 )
2018
18
A high expression of cell adhesion molecule 1 (CADM1) is an unfavorable prognostic factor in mycosis fungoides. ( 29391198 )
2018
19
Etoposide as a single agent in the treatment of mycosis fungoides: A retrospective analysis. ( 29316111 )
2018
20
Hypopigmented mycosis fungoides: a 20-case retrospective series. ( 29318586 )
2018
21
Folliculotropic mycosis fungoides presenting with a solitary lesion: Clinicopathological features and long-term follow-up data in a series of 9 cases. ( 29086994 )
2018
22
Clinical and histological evaluation in patients with mycosis fungoides treated with UVA1. ( 29368862 )
2018
23
Recalcitrant acquired palmoplantar keratoderma: Think about Mycosis fungoides. ( 29903407 )
2018
24
Case report: photo-onycholysis after PUVA treatment for hypopigmented mycosis fungoides with response to topical steroid. ( 29445460 )
2018
25
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome. ( 29196934 )
2018
26
Lack of detectable effect of narrow-band ultraviolet B on peripheral blood mononuclear cell cytokine expression in early-stage mycosis fungoides. ( 29851171 )
2018
27
Perplexing Rash: Challenges to Diagnosis and Management of Mycosis Fungoides. ( 29946665 )
2018
28
Occurrence of Mycosis Fungoides in an Iranian Chemical Victim of the Iran-Iraq War with a Long-term Follow-Up: A Case Report and Review of Literature. ( 29892151 )
2018
29
Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B cell Lymphoma and Acute Myeloid Leukemia: A Report of Two Cases. ( 29321428 )
2018
30
Eosinophilic infiltrate resembling eosinophilic cellulitis (Wells syndrome) in a patient with mycosis fungoides. ( 29469767 )
2018
31
Retinoic Acid Receptor Agonist as Monotherapy for Early-Stage Mycosis Fungoides: Does it Work? ( 29889596 )
2018
32
The importance of lymph node examination: Simultaneous diagnosis of hypopigmented mycosis fungoides and follicular B-cell lymphoma. ( 29942830 )
2018
33
Juvenile-Onset Early-Stage Mycosis Fungoides-Associated Follicular Mucinosis: A Case Report. ( 29927752 )
2018
34
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. ( 29947731 )
2018
35
Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data. ( 29440874 )
2018
36
A unique combination of Rosai-Dorfman disease and mycosis fungoides: a case report. ( 29854404 )
2018
37
Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis. ( 29108666 )
2018
38
Successful treatment of extensive splanchnic vein thrombosis in a patient with mycosis fungoides. ( 29437735 )
2018
39
Decreased IL-10-producing regulatory B cells in patients with advanced mycosis fungoides. ( 29952298 )
2018
40
Folliculotropic Mycosis Fungoides in 20 Korean Cases: Clinical and Histopathologic Features and Response to Ultraviolet A-1 and/or Photodynamic Therapy. ( 29606817 )
2018
41
Hypopigmented Mycosis Fungoides Treated with 308 nm Excimer Laser. ( 29386841 )
2018
42
Imaging of Chemokine Receptor CXCR4 in Mycosis Fungoides Using 68Ga-Pentixafor PET/CT. ( 29916918 )
2018
43
Acneiform follicular mucinosis: an indolent follicular mucinosis variant unrelated to mycosis fungoides? ( 29851124 )
2018
44
Folliculotropic mycosis fungoides. ( 29726638 )
2018
45
Mycosis fungoides progression could be regulated by microRNAs. ( 29894486 )
2018
46
Exacerbation of mycosis fungoides leading to the diagnosis of chronic myelomonocytic leukemia. ( 29687069 )
2018
47
Reflectance Confocal Microscopy as New Diagnostic Tool in Folliculotropic Mycosis Fungoides. ( 29765972 )
2018
48
The Modified Severity-Weighted Assessment Tool: A PASI/EASI System for Mycosis Fungoides. ( 29898821 )
2018
49
Relationship Between Pityriasis Lichenoides and Mycosis Fungoides: A Clinicopathological, Immunohistochemical, and Molecular Study. ( 29210716 )
2017
50
Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome. ( 28648940 )
2017
Sources

Variations for Mycosis Fungoides

About this section

Cosmic variations for Mycosis Fungoides:

9
(show top 50) (show all 92)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5574244 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2668A>C p.T890P 10:31523999-31523999 20
2 COSM5574236 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.517C>T p.P173S 10:31510708-31510708 20
3 COSM5574238 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.752A>G p.Y251C 10:31514670-31514670 20
4 COSM44854 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.655C>A p.P219T 17:7674876-7674876 20
5 COSM44036 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.296C>T p.S99F 17:7676073-7676073 20
6 COSM44312 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.511G>A p.E171K 17:7675101-7675101 20
7 COSM45449 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.592G>C p.E198Q 17:7674939-7674939 20
8 COSM45796 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.623A>G p.D208G 17:7674908-7674908 20
9 COSM10768 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.535C>T p.H179Y 17:7675077-7675077 20
10 COSM11073 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1024C>T p.R342* 17:7670685-7670685 20
11 COSM11166 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.406C>T p.Q136* 17:7675206-7675206 20
12 COSM5574229 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1918C>T p.Q640* 4:105235860-105235860 20
13 COSM42016 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4393C>T p.R1465* 4:105272774-105272774 20
14 COSM5574231 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.521C>A p.P174H 4:105234463-105234463 20
15 COSM100075 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4193T>C p.L1398P 4:105272574-105272574 20
16 COSM110772 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4474G>T p.E1492* 4:105272855-105272855 20
17 COSM1716590 STAT5B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1924A>C p.N642H 17:42207711-42207711 20
18 COSM1717514 STAT3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1492A>G p.I498V 17:42324819-42324819 20
19 COSM1155743 STAT3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1919A>T p.Y640F 17:42322464-42322464 20
20 COSM5574219 SETD1A haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1211G>A p.R404H 16:30964953-30964953 20
21 COSM5104 PTEN haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.392C>T p.T131I 10:87933151-87933151 20
22 COSM5159 PTEN haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.733C>T p.Q245* 10:87957951-87957951 20
23 COSM23568 PTEN haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.919G>A p.E307K 10:87961011-87961011 20
24 COSM3734685 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1034C>T p.S345F 20:41163944-41163944 20
25 COSM5049787 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1025A>G p.D342G 20:41163935-41163935 20
26 COSM5049788 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1024G>A p.D342N 20:41163934-41163934 20
27 COSM3405078 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3487G>A p.E1163K 20:41173744-41173744 20
28 COSM3734686 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1559C>T p.S520F 20:41165499-41165499 20
29 COSM5574251 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3473G>A p.R1158H 20:41173730-41173730 20
30 COSM5613080 PIK3CA haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1609C>T p.R537* 3:179218279-179218279 20
31 COSM580 NRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.181C>A p.Q61K 1:114713909-114713909 20
32 COSM4591233 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.534G>C p.K178N 17:16165063-16165063 20
33 COSM126825 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2125C>T p.Q709* 17:16108843-16108843 20
34 COSM5574213 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3360G>C p.E1120D 17:16080448-16080448 20
35 COSM5574204 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.6038C>T p.P2013L 17:16058037-16058037 20
36 COSM5574211 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.6322C>T p.Q2108* 17:16057584-16057584 20
37 COSM5574208 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.76C>A p.Q26K 17:16194494-16194494 20
38 COSM532 KRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.38G>A p.G13D 12:25245347-25245347 20
39 COSM5574196 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.11845C>T p.Q3949* 12:49032050-49032050 20
40 COSM5574193 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4475G>C p.S1492T 12:49043902-49043902 20
41 COSM30358 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.7495G>A p.D2499N 12:49039283-49039283 20
42 COSM5574203 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.5923C>G p.L1975V 12:49041037-49041037 20
43 COSM5574250 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3067T>C p.Y1023H 19:17830532-17830532 20
44 COSM34214 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1715C>T p.A572V 19:17837200-17837200 20
45 COSM51374 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1533G>A p.M511I 19:17838299-17838299 20
46 COSM3734693 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1975C>T p.R659C 1:64846661-64846661 20
47 COSM5574248 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2128C>G p.L710V 1:64844877-64844877 20
48 COSM2239136 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1961A>T p.Y654F 1:64846675-64846675 20
49 COSM5574188 DNMT3B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2292G>T p.R764S 20:32805398-32805398 20
50 COSM1025793 DNMT3B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.895C>T p.R299* 20:32791682-32791682 20
Sources

Expression for Mycosis Fungoides

About this section
Search GEO for disease gene expression data for Mycosis Fungoides.
Sources

Pathways for Mycosis Fungoides

About this section

Pathways related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.99 CCL22 CD28 CTLA4 IFNA1 IFNA2 IL2
2
ERK Signaling 64
Show member pathways
 13.75 CCL17 CCL22 CCR4 CD28 CDKN2B CXCR3
3
PEDF Induced Signaling 64
Show member pathways
 13.56 CCL17 CCL22 CCR4 CD28 CXCR3 IFNA1
4
TGF-Beta Pathway 64
Show member pathways
 13.43 CCL17 CCL22 IFNA1 IFNA2 IL2 IL2RA
5
Integrin Pathway 64
Show member pathways
 13.35 CCL17 CCL22 CCR4 CXCR3 ITGAE ITGB2
6
Cytokine Signaling in Immune system 66
Show member pathways
 13.33 CCL22 IFNA1 IFNA2 IL2 IL2RA IL5
7
PAK Pathway 64
Show member pathways
 13.24 CCL17 CCL22 CCR4 CD28 CXCR3 IL2
8
Akt Signaling 64
Show member pathways
 13.11 CCL17 CCL22 CCR4 CD28 CXCR3 IL2
9
Pathways in cancer 37
12.83 CDKN2B IFNA1 IFNA2 IL2 IL2RA IL5
10
CCR5 Pathway in Macrophages 64
Show member pathways
 12.82 CCL17 CCL22 CCR4 CXCR3 STAT3
11
Allograft rejection 1 37
Show member pathways
 12.76 CD28 CTLA4 IFNA1 IFNA2 IL2 IL2RA
12
Influenza A 37
Show member pathways
 12.75 CD28 IFNA1 IFNA2 IL2 IL2RA STAT3
13
Regulation of IFNA signaling 66
Show member pathways
 12.62 IFNA1 IFNA2 IL2 IL2RA IL5 STAT3
14
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.45 IFNA1 IFNA2 IL2 ITGB2
15
Th17 cell differentiation 37
Show member pathways
 12.38 IL2 IL2RA IL5 STAT3
16
T cell receptor signaling pathway 37
Show member pathways
 12.36 CD28 CTLA4 IL2 IL5
17
HTLV-I infection 37
12.35 CDKN2B IL2 IL2RA ITGB2
18
ICos-ICosL Pathway in T-Helper Cell 64
Show member pathways
 12.32 CD28 CTLA4 IL2 IL2RA
19
Immune response Antigen presentation by MHC class II 22
Show member pathways
 12.15 CD28 IL2 IL2RA STAT3
20
NF-kappaB Signaling 4
12.12 CD28 CTLA4 IFNA1 IL2 IL2RA ITGB2
21
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.07 CCL17 CCL22 IL2 IL2RA IL5 STAT3
22
MAPK Pathway 72
Show member pathways
 12.01 IL2 IL2RA IL5 STAT3
23
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
12 CD28 IFNA2 IL2 IL2RA IL5
24
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 65
Show member pathways
 11.96 CCL17 CCL22 CCR4 CXCR3
25
Interleukin-4 and 13 signaling 66
11.95 CCL22 ITGB2 STAT3 TNFRSF1B
26
IL12-mediated signaling events 1
Show member pathways
 11.9 IL2 IL2RA STAT3
27
Jak-Stat Signaling Pathway 67
11.9 IFNA1 IFNA2 IL2 IL2RA STAT3
28
Hematopoietic cell lineage 37
11.83 CD7 IL2RA IL5
29
Rheumatoid arthritis 37
11.79 CD28 CTLA4 ITGB2
30
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.76 CTLA4 IL2 IL2RA IL5
31
Dendritic Cells Developmental Lineage Pathway 65
11.68 IFNA2 IL2 ITGAE
32
Innate Lymphoid Cell Differentiation Pathways 65
11.64 CD7 CXCR3 IL2 IL2RA IL5 ITGAE
33
T Cell Co-Signaling Pathway: Ligand-Receptor Interactions 65
11.57 CD28 CTLA4 TNFRSF8
34
Interleukin-10 signaling 66
11.49 CCL22 STAT3 TNFRSF1B
35
T-Cell Receptor and Co-stimulatory Signaling 1
11.27 CD28 CTLA4 IL2
36
IL12 signaling mediated by STAT4 1
11.24 CD28 IL2 IL2RA STAT3
37
Inflammatory Response Pathway 1
11.24 CD28 IL2 IL2RA IL5 TNFRSF1B
38
Th2 Differentiation Pathway 65
10.76 CCL17 CCL22 CD28 IL2 IL2RA IL5
Sources

GO Terms for Mycosis Fungoides

About this section

Cellular components related to Mycosis Fungoides according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.93 CCR4 CD28 CD7 CTLA4 CXCR3 DPP4
2 external side of plasma membrane GO:0009897 9.17 CCR4 CD28 CTLA4 CXCR3 IL2RA ITGAE
3 protein complex involved in cell adhesion GO:0098636 8.96 CD28 CTLA4

Biological processes related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.88 CCL17 CCL22 IFNA2 IL2 ITGB2
2 regulation of signaling receptor activity GO:0010469 9.85 CCL17 CCL22 IFNA1 IFNA2 IL2 IL5
3 cell surface receptor signaling pathway GO:0007166 9.83 CD28 CXCR3 IFNA2 IL2RA TNFRSF1B
4 chemotaxis GO:0006935 9.81 CCL17 CCL22 CCR4 CXCR3
5 cytokine-mediated signaling pathway GO:0019221 9.81 CCL22 IFNA1 IFNA2 IL2 IL2RA IL5
6 adaptive immune response GO:0002250 9.8 CD7 CTLA4 IFNA1 IFNA2 IL2
7 negative regulation of inflammatory response GO:0050728 9.79 IL2 IL2RA TNFRSF1B
8 apoptotic signaling pathway GO:0097190 9.78 CD28 TNFRSF1B TNFRSF8
9 T cell costimulation GO:0031295 9.77 CD28 CTLA4 DPP4
10 neutrophil chemotaxis GO:0030593 9.75 CCL17 CCL22 ITGB2
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.74 IFNA2 IL2 STAT3
12 positive regulation of T cell proliferation GO:0042102 9.73 CD28 IL2 IL2RA
13 humoral immune response GO:0006959 9.72 CD28 IFNA1 IFNA2
14 immune response GO:0006955 9.7 CCL17 CCL22 CCR4 CD28 CD7 CTLA4
15 T cell activation GO:0042110 9.67 CD28 CD7 DPP4
16 chemokine-mediated signaling pathway GO:0070098 9.62 CCL17 CCL22 CCR4 CXCR3
17 positive regulation of immunoglobulin secretion GO:0051024 9.61 IL2 IL5
18 interleukin-2-mediated signaling pathway GO:0038110 9.6 IL2 IL2RA
19 positive regulation of isotype switching to IgG isotypes GO:0048304 9.58 CD28 IL2
20 regulation of regulatory T cell differentiation GO:0045589 9.56 CD28 CTLA4 IL2 IL2RA
21 negative regulation of lymphocyte proliferation GO:0050672 9.52 IL2 IL2RA
22 regulation of T cell homeostatic proliferation GO:0046013 9.46 IL2 IL2RA
23 inflammatory response GO:0006954 9.36 CCL17 CCL22 CCR4 CXCR3 IFNA2 IL2RA
24 apoptotic process GO:0006915 10.01 CXCR3 IFNA2 IL2RA ITGB2 TIA1 TNFRSF1B

Molecular functions related to Mycosis Fungoides according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 CCL17 CCL22 IFNA1 IFNA2 IL2 IL5
2 type I interferon receptor binding GO:0005132 8.96 IFNA1 IFNA2
Sources

Sources for Mycosis Fungoides

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....